Astec LifeSciences Limited
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maiz… Read more
Astec LifeSciences Limited (ASTEC) - Total Liabilities
Latest total liabilities as of September 2025: ₹4.69 Billion INR
Based on the latest financial reports, Astec LifeSciences Limited (ASTEC) has total liabilities worth ₹4.69 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Astec LifeSciences Limited - Total Liabilities Trend (2008–2025)
This chart illustrates how Astec LifeSciences Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Astec LifeSciences Limited Competitors by Total Liabilities
The table below lists competitors of Astec LifeSciences Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ablerex Electronics Co Ltd
TWO:3628
|
Taiwan | NT$1.95 Billion |
|
Tainet Communication System
TWO:4905
|
Taiwan | NT$1.48 Billion |
|
Take Solutions Limited
NSE:TAKE
|
India | ₹95.84 Million |
|
Dmg Blockchain Solutions Inc
OTCQB:DMGGF
|
USA | $17.44 Million |
|
Aallon Group Oyj
HE:AALLON
|
Finland | €19.44 Million |
|
Trans Power Marine Tbk
JK:TPMA
|
Indonesia | Rp2.08 Trillion |
Liability Composition Analysis (2008–2025)
This chart breaks down Astec LifeSciences Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Astec LifeSciences Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Astec LifeSciences Limited (2008–2025)
The table below shows the annual total liabilities of Astec LifeSciences Limited from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹6.46 Billion | +6.77% |
| 2024-03-31 | ₹6.05 Billion | +8.14% |
| 2023-03-31 | ₹5.60 Billion | +11.95% |
| 2022-03-31 | ₹5.00 Billion | +35.80% |
| 2021-03-31 | ₹3.68 Billion | +13.37% |
| 2020-03-31 | ₹3.25 Billion | +25.76% |
| 2019-03-31 | ₹2.58 Billion | +6.18% |
| 2018-03-31 | ₹2.43 Billion | +24.48% |
| 2017-03-31 | ₹1.95 Billion | -23.21% |
| 2016-03-31 | ₹2.54 Billion | +11.75% |
| 2015-03-31 | ₹2.28 Billion | +32.85% |
| 2014-03-31 | ₹1.71 Billion | +10.44% |
| 2013-03-31 | ₹1.55 Billion | +16.94% |
| 2012-03-31 | ₹1.33 Billion | +61.59% |
| 2011-03-31 | ₹821.40 Million | +35.52% |
| 2010-03-31 | ₹606.13 Million | -6.89% |
| 2009-03-31 | ₹650.98 Million | +17.16% |
| 2008-03-31 | ₹555.62 Million | -- |